Dr. Russell Rother - 2012
Dr. Russell Rother is a 1986 biology graduate of SWOSU who has been with Selexys Pharmaceuticals since 2010 where he manages the clinical trials for a therapeutic designed to treat sickle cell disease. He is also the liaison with the Food and Drug Administration and oversees research activities at the company.
Before joining Selexys, Rother was senior vice president and chief scientific officer at Alexion Pharmaceuticals in Cheshire (CT) from 1992-2010 where he was one of the original scientists at the company. He played a critical role in the engineering and development of Alexion’s antibody therapeutics and led discovery efforts in the identification of new indications and novel drug targets.
Rother was instrumental in strategic decisions for Alexion to initiate the paroxysmal nocturnal hemogobinuria (PNH) program, playing a major role in the development of Soliris (eculizumab), the first therapy approved for the treatment of PNH. This drug alone has provided Alexion with an $800 million revenue stream and $15 billion market cap to date.
Before leaving Alexion, he was managing the Departments of Research, Scientific Communications, Medical Information, Bioanalytical Development and Biometrics.
Rother, who is a graduate of Watonga High School, earned his doctorate in 1991 from the University of Oklahoma Health Sciences Center. He was a Postdoctoral Fellow at the Yale School of Medicine in 1991-92. Rother serves as a board member for Variety Care Foundation and Docvia. He holds 32 issued patents/patent applications and has had numerous articles in a variety of publications.